肝动脉化疗栓塞联合靶向免疫疗法治疗原发性肝癌的疗效

doi:10.3969/j.issn.1671-7171.2025.05.007

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1215 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the clinical efficacy of transarterial chemoembolization (TACE) combined with targeted immunotherapy in the treatment of primary liver cancer.【Methods】 A total of 80 patients with primary liver cancer were divided into the control group (37 cases, treated with TACE alone) and the observation group (43 cases, treated with TACE combined with targeted immunotherapy) based on different treatment modalities. The clinical efficacy, changes in liver function indicators, incidence of complications, and survival outcomes were compared between the two groups.【Results】 The objective response rate and disease control rate in the observation group were higher than those in the control group (P<0.05). After treatment, liver function in both groups improved compared to pre-treatment levels, with the observation group showing a more significant improvement than the control group (P<0.05). There was no significant difference in the incidence of complications between the two groups (P>0.05). The 1-year survival rate, overall survival, and progression-free survival in the observation group were superior to those in the control group (P<0.05).【Conclusion】 TACE combined with targeted immunotherapy can improve the objective response rate and disease control rate, enhance liver function, and prolong survival in patients with primary liver cancer, demonstrating significant clinical value.

Key words： Liver Neoplasms Chemoembolization, Therapeutic Immunotherapy Treatment Outcome

Received: 15 November 2024

PACS:

R735.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YE Cheng
	WANG Jianan
	ZHU Xiaoxu

Cite this article:

YE Cheng,WANG Jianan,ZHU Xiaoxu. Clinical Efficacy of Transarterial Chemoembolization Combined with Targeted Immunotherapy for Primary Liver Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(5): 758-760.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.05.007 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I5/758

[1] 李爽,刘哲睿,赵琦,等.嵌合抗原受体T细胞治疗原发性肝癌临床研究进展[J].临床肝胆病杂志,2023,39(5):1019-1029.
[2] 房启楼,倪建勋,范红星,等.TACE联合纳米粒治疗早期肝癌并发门静脉高压的疗效及安全性[J].肝脏,2021,26(1):51-54.
[3] SOTHEA Y,孙慧怡,王飞航,等.TACE同步微波消融与TACE治疗不同病理分级神经内分泌肿瘤肝转移的临床疗效比较[J].复旦学报(医学版),2024,51(3):323-330.
[4] 张迪,陈浩然,王家政,等.肺癌分子靶向治疗EGFR-TKI患者证候及中医处方用药研究进展[J].中华中医药学刊,2024,42(4):171-174.
[5] 王艺璇,陈鑫杰,杨芳,等.免疫联合放疗治疗难治性三阴性乳腺癌骨转移1例报道及文献复习[J].中国肿瘤生物治疗杂志,2024,31(4):422-424.
[6] 焦泉慧,钟凌云,程子文,等.中药及其天然产物通过靶向铁死亡治疗癌症研究进展[J].医药导报,2024,43(3):408-413.
[7] 陆嘉宁,马佩,高雯,等.75岁以上癌症患者免疫治疗相关不良反应的回顾性分析[J].南京医科大学学报(自然科学版),2023,43(5):640-647.
[8] AJOOLABADY A, TANG D, KROEMER G, et al. Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy[J].Br J Cancer,2023, 128(2):190-205.
[9] 朱九荣,岳恺,叶亚平,等.甲苯磺酸索拉非尼联合TACE术用于不可手术切除的局限性肝癌患者治疗的效果分析[J].实用癌症杂志,2024,39(4):648-651.[10] 王宏博,刘福晨,刘辉,等.经肝动脉化疗栓塞术联合多纳非尼与替雷利珠单抗治疗中晚期肝癌34例[J].临床放射学杂志,2024,43(3):443-449.
[11] 张辉,张庆桥,袁磊,等.CalliSpheres D-TACE与c-TACE治疗原发性肝癌对肝纤维化和肝功能的影响[J].介入放射学杂志,2024,33(3):259-263.
[12] 杨永净,柯天洋,刘士新,等.甲磺酸阿帕替尼联合放疗对肝癌HepG2细胞的体外协同增敏作用[J].吉林大学学报(医学版),2024,50(4):1009-1015.
[13] 邸亮,阿卜力皮孜·阿卜力克木,郭庆良,等.卡瑞利珠单抗联合射频消融术治疗肝硬化肝癌患者的临床疗效及安全性[J].疑难病杂志,2024,23(3):318-322.
[14] 姚红兵,吴杰松,熊艺晶,等.经肝动脉介入化疗联合靶向治疗与免疫治疗在不可切除原发性肝细胞癌患者中的应用[J].癌症进展,2024,22(12):1343-1348.
[15] 韩传军,黄剑辉,陈佳.TACE联合靶向药物治疗晚期原发性肝癌患者的疗效[J].中国肿瘤外科杂志,2023,15(4):368-372.
[16] JU S G, ZHOU C, HU J W, et al. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination[J].BMC Cancer,2022, 22(1):335.